Alcidion has raised capital
Alcidion Group Ltd. (ASX:ALC) has raised capital via an institutional placement. The placement was well supported by existing shareholders whilst also welcoming several new institutional shareholders to the register. Proceeds from the raise will provide Alcidion with maximum flexibility and ensure a strong balance sheet to execute on its market opportunities and enable the firm to continue to drive revenue growth.
Alcidion is a market leading healthcare software informatics company providing an innovative technology platform to improve the efficiency and quality of patient care. Its flagship platform, Miya Precision, can be deployed in a modular approach to accommodate varying customer priorities and budget profiles across the UK, Australia and New Zealand markets.
At the end of September 2023, Alcidion had A$35.3 million (US$23m) of contracted revenue for FY24 (expected to grow over the remainder of the year) and is forecasting to be EBITDA and cashflow positive.
Oaklins’ team in Australia acted as lead manager in this transaction.
Discuti con...
Justin Lewis
Oaklins Henslow
Deal relazionato
RAM Infotechnology has acquired Interoperability Group with support from Keensight Capital
RAM Infotechnology (RAM-IT) has acquired Interoperability Group, a leading Dutch provider of healthcare IT solutions, with the support of Keensight Capital, a leading European growth buy-out investor specializing in technology and healthcare.
Per saperne di piùToivo Group has succesfully transferred to the Main Market of Nasdaq Helsinki
Toivo Group Plc has taken a significant strategic step by transferring to the Main Market of Nasdaq Helsinki. This move supports the company’s ambition for sustainable growth and reinforces its position as a key player in the Finnish residential development sector.
Per saperne di piùCerbios-Pharma has been acquired by HAS Healthcare
Cerbios-Pharma S.A. has been acquired by HAS Healthcare Advanced Synthesis S.A., forming a leading global contract development and manufacturing organization (CDMO) group. This transaction results in a seamless integration of complementary capabilities, combining extensive expertise in production, chemical and biological sciences and technical excellence, all designed to meet the evolving demands of the global pharmaceutical sector.
Per saperne di più